SpliSense gets US FDA fast track designation for antisense oligonucleotide product, SPL84 for treatment of cystic ...
SpliSense, a clinical-stage biotechnology company focused on the development of transformative RNA-based therapies for pulmonary diseases including cystic fibrosis (CF), muco-obstructive diseases like COPD, asthma and NCFB and idiopathic pulmonary fibrosis …